Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

J R Hecht, S S Raman, A Chan, K Kalinsky, J-F Baurain, M M Jimenez, M M Garcia, M D Berger, U M Lauer, A Khattak, A Carrato, Y Zhang, K Liu, E Cha, A Keegan, S Bhatta, C P Strassburg, A Roohullah, J R Hecht, S S Raman, A Chan, K Kalinsky, J-F Baurain, M M Jimenez, M M Garcia, M D Berger, U M Lauer, A Khattak, A Carrato, Y Zhang, K Liu, E Cha, A Keegan, S Bhatta, C P Strassburg, A Roohullah

Abstract

Background: Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation. T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than either agent alone. Safety/efficacy of the combination was explored in patients with triple negative breast cancer (TNBC) or colorectal cancer (CRC) with liver metastases.

Methods: In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU/ml; ≤4 ml) was administered into hepatic lesions via image-guided injection every 21 (±3) days. Atezolizumab 1200 mg was given on day 1 and every 21 (±3) days thereafter. Treatment continued until patients experienced dose-limiting toxicity (DLT), had complete response, progressive disease, needed alternative anticancer treatment, or withdrew due to an adverse event (AE). The primary endpoint was DLT incidence, and secondary endpoints included efficacy and AEs.

Results: Between 19 March 2018 and 6 November 2020, 11 patients with TNBC were enrolled (safety analysis set: n = 10); between 19 March 2018 and 16 October 2019, 25 patients with CRC were enrolled (safety analysis set: n = 24). For the 5 patients in the TNBC DLT analysis set, no patient had DLT; for the 18 patients in the CRC DLT analysis set, 3 (17%) had DLT, all serious AEs. AEs were reported by 9 (90%) TNBC and 23 (96%) CRC patients, the majority with grade ≥3 [TNBC, 7 (70%); CRC, 13 (54%)], and 1 was fatal [CRC, 1 (4%)]. Evidence of efficacy was limited. Overall response rate was 10% (95% confidence interval 0.3-44.5) for TNBC; one (10%) patient had a partial response. For CRC, no patients had a response; 14 (58%) were unassessable.

Conclusions: The safety profile reflected known risks with T-VEC including risks of intrahepatic injection; no unexpected safety findings from addition of atezolizumab to T-VEC were observed. Limited evidence of antitumor activity was observed.

Keywords: breast neoplasms; drug therapy combination; gastrointestinal neoplasms; viral immunotherapy; virotherapy.

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
CONSORT diagram (A) TNBC and (B) CRC. CRC, colorectal cancer; T-VEC, talimogene laherparepvec; TNBC, triple negative breast cancer.
Figure 2
Figure 2
Kaplan–Meier plot for PFSa in (A) TNBC and (B) CRC, and OSb in (C) TNBC and (D) CRC for all patients who have received ≥1 dose of T-VEC or atezolizumab. CI, confidence interval; CRC, colorectal cancer; irRC-RECIST, immune-related response criteria simulating Response Evaluation Criteria in Solid Tumors; NE, non-estimable; OS, overall survival; PFS, progression-free survival; TNBC, triple negative breast cancer; T-VEC, talimogene laherparepvec. aPFS per modified irRC-RECIST is the interval from the first dose to the earlier of patient overall response of progressive disease or death from any cause; PFS is censored at the later of their last assessable tumor assessment or date of first dose. bOS is the interval from the first dose to death from any cause; OS is censored at the date the patient was last known to be alive.

References

    1. Kohlhapp F.J., Kaufman H.L. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048–1054.
    1. Liu B.L., Robinson M., Han Z.Q., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
    1. IMLYGIC® (talimogene laherparepvec). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2023. Available at (). Accessed February 22, 2023.
    1. IMLYGICTM. Summary of Product Characteristics. London, UK: European Medicines Agency; 2020. Available at . Accessed February 22, 2023.
    1. TECENTRIQ (Atezolizumab). Full Prescribing Information. South San Francisco, CA: Genentech Inc.; 2022. Available at (). Accessed February 22, 2023.
    1. European Medicines Evaluation Agency. Tecentriq: summary of product characteristics. Available at . Accessed February 16, 2023.
    1. Schmid P., Adams S., Rugo H.S., et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
    1. Roche. Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. Available at . Accessed September 14, 2021.
    1. Miles D., Gligorov J., André F., et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004.
    1. Emens L.A., Cruz C., Eder J.P., et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82.
    1. OPDIVO (Nivolumab). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2022. Available at . Accessed February 17, 2023.
    1. KEYTRUDA (Pembrolizumab). Full Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2023. Available at . Accessed February 16, 2023.
    1. Golshani G., Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol. 2020;13
    1. Rousseau B., Bieche I., Pasmant E., et al. PD-1 blockade in solid tumors with defects in polymerase epsilon. Cancer Discov. 2022;12(6):1435–1448.
    1. Ribas A., Dummer R., Puzanov I., et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e10.
    1. Ribas A., Chesney J., Long G.V., et al. MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage III-IVM1c melanoma (MEL) Ann Oncol. 2021;32(suppl 5):S868–S869.
    1. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948.
    1. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–259.
    1. Lin N.U., Claus E., Sohl J., Razzak A.R., Arnaout A., Winer E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–2645.
    1. Disibio G., French S.W. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132(6):931–939.
    1. Yu J., Green M.D., Li S., et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152–164.
    1. Kwan A., Winder N., Muthana M. Oncolytic virotherapy treatment of breast cancer: barriers and recent advances. Viruses. 2021;13(6):1128.
    1. Chaurasiya S., Warner S. Viroimmunotherapy for colorectal cancer: clinical studies. Biomedicines. 2017;5(1):11.
    1. Bernstein V., Ellard S.L., Dent S.F., et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. 2018;167(2):485–493.
    1. Miller K., Zhao F., Clark A., Wilkinson G., Laeufle R., Wolff A. Abstract OT-13-02: Bracelet-1 (pre0113): a study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel. Cancer Res. 2021;81(suppl 4) OT-13-02.
    1. Hecht J.R., Prat A., Pless M., et al. A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318) J Clin Oncol. 2018;36(suppl) abstr TPS3105.
    1. Ferrucci P.F., Pala L., Conforti F., Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel) 2021;13(6):1383.
    1. . Single-arm trial to evaluate the role of the immune response to talimogene laherparepvec in unresected melanoma (TVEC-325) (NCT02366195). Available at . Accessed February 16, 2023.
    1. Melero I., Castanon E., Alvarez M., Champiat S., Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18(9):558–576.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner